Amman – Dr. Fadi Al-Atrash, representative of the Therapeutic Industries and Medical Supplies Sector at the Jordan Chamber of Industry, praised King Abdullah II’s visit to Dar Al-Dawaa Company, which specializes in manufacturing pharmaceutical products and healthcare items.
اضافة اعلان
In an interview with the Jordan News Agency (Petra), Dr. Al-Atrash emphasized that the King's visit underscores his continuous attention and follow-up to the pharmaceutical industry sector, which is considered one of the main pillars of the economic modernization vision and a high-value industry.
He added that the Jordanian pharmaceutical industry enjoys the King's support, as he consistently directs efforts to provide full support to the companies in this sector and remove any obstacles they face, enabling them to continue their growth, development, and global competitiveness.
Dr. Al-Atrash pointed out that this royal support has given factories and producing companies a strong boost to continue their work, turning the Jordanian pharmaceutical industry into a "cross-border" industry that competes vigorously in both Arab and international export markets, as well as contributing to achieving pharmaceutical security in the Kingdom.
He further explained that pharmaceutical manufacturers and producers are continuing to expand their operations, increase investments, and implement initiatives outlined in the economic modernization vision, translating His Majesty’s emphasis on self-reliance into reality, benefiting the national economy.
The pharmaceutical sector in Jordan, according to Dr. Al-Atrash, is pioneering, with significant potential for growth, and acts as an enabler for other sectors, contributing to economic growth and job creation.
He added that the inclusion of the pharmaceutical sector in the economic modernization vision reflects its importance as a vital contributor to the Jordanian economy. The vision aims to elevate the sector to make Jordan a regional hub for pharmaceutical products.
Dr. Al-Atrash explained that the sector has a high added value, reaching 55% of total production, equivalent to approximately 850 million Jordanian dinars.
He noted that the economic modernization vision has placed the pharmaceutical sector at the top of its priorities, as it is a vital industry growing steadily. The vision includes many initiatives and strategies that aim to empower and support the sector, removing barriers to ensure its continued growth and success, keeping the Jordanian pharmaceutical industry at the forefront for decades.
The Jordanian pharmaceutical industry, which began with the establishment of the first factory in 1962 in Salt, enjoys excellent quality and reputation, enabling it to compete globally and lead the regional market in terms of quality, product diversity, and the ability to enter non-traditional export markets.
Dr. Al-Atrash also praised the role of official entities, particularly the Jordan Food and Drug Administration (JFDA), for their continuous efforts to support the development of pharmaceutical products through ongoing monitoring and the introduction of modern systems and regulations that have contributed to advancing the Jordanian pharmaceutical industry.
He pointed out that Jordan has numerous export opportunities in various industrial sectors, especially therapeutic industries and medical supplies, which are valued at over 515 million dollars for different countries.
Exports from the therapeutic industries sector grew by 9% in 2024, reaching nearly 809 million dinars, representing about 9% of total industrial exports.
Dr. Al-Atrash added that, due to the ongoing improvements in the pharmaceutical industry’s performance, the added value of the sector has significantly increased, now accounting for more than 51% of the total production in the sector.
He also mentioned that these developments have positively impacted the sector’s contribution to the national economy, which now stands at about 3% of the Kingdom's GDP. Jordanian pharmaceutical products are present in 85 export markets, including Saudi Arabia, Iraq, the United States, the UAE, Algeria, and Yemen.
The human pharmaceutical industry in Jordan represents 85% of the total therapeutic industries and medical supplies sector, with 27 facilities across the country. The sector has a registered capital of approximately 280 million dinars and provides 10,000 jobs, 35% of which are held by women.
.jpg)
.jpg)
